This week's bullish stocks in Hong Kong | High-dividend stocks are sought after! China's foreign transport week rose by more than 23%, and China's building materials rose by more than 17%
In terms of individual stocks, net revenue from Q1 products increased by nearly 40% year on year, and Zaiding Pharmaceutical soared more than 26% this week; pre-sale of new iPad products began! The Apple concept stock, BYD shares surged nearly 20% this week.
A quick look at the Hong Kong market | The three major indices have collectively pulled back, and the science index fell more than 2% to 4,000 points; domestic housing stocks rose against the market, and Xincheng Development rose nearly 6%
Technology Network stocks generally fell; Bilibili fell more than 6%, Kuaishou fell nearly 5%, and Meituan fell nearly 4%; copper concept stocks strengthened, Wanguo International Mining rose nearly 10%, and China's nonferrous mining industry rose more than 4%.
Express News | Hong Kong stocks generally fell by “Pharmacology”. Pharmacovigilance fell by more than 10%. At one point, Yao Ming Biotech and Pharmaceutical Kangde fell by more than 7%.
WuXi XDC Cayman's Profit Up 82% in 2023
WuXi XDC Cayman (HKG:2268) recorded an 82% rise in attributable profit for the year 2023 to 283.5 million yuan from 155.7 million yuan in 2022, according to the company's annual report posted on the H
藥明合聯:2023年度報告
Pharmaceutical Federation (2268.HK): Significantly increasing the upper limit demand for raw material procurement agreements and continuing high order growth
Incident: On April 26, 2024, the Pharmaceutical Federation issued an announcement. The company will raise the upper limit of the raw material procurement service agreement from Yangming Biotech from 32.6 million yuan to 80.0 million yuan (+145%) in 2024.
A quick overview of the Hong Kong market | Hong Kong stocks are rising across the board! The Tech Index surged more than 3%, Kuaishou surged nearly 9%, and Meituan rose nearly 8%
Many biotech stocks rose; Lai Kai Pharmaceutical rose nearly 13%, Kangfang Biotech rose nearly 6%; gold stocks declined, Lingbao Gold fell nearly 4%, and Zijin Mining fell more than 3%.
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
Changes in Hong Kong stocks | Pharmaceutical Federation (02268) is now up more than 6%, and the company's performance is doubling, and global production capacity is being released at an accelerated pace
Pharmaceutical Federation (02268) is now up more than 6%. As of press release, it is up 6.51% to HK$19.96, with a turnover of HK$488.745 million.
Most of the Hong Kong pharmaceutical stocks rose, and Pharmacovigilance rose nearly 9%
As of press release, Pharmacomide is up 8.86%, Cansino Biotech is up 5.26%, and Medicinal Kangde is up 2.85%.
Big benefits have arrived! Pharmacovigilance is getting stronger. What's the situation?
Yao Ming Kangde's deep participation in the US healthcare field has far surpassed congressional discussions. Some senior members of the country's biotech industry have clearly opposed the bill.
Changes in Hong Kong stocks | Yao Ming Union (02268) surged more than 5% in the afternoon, and the company achieved a further breakthrough in the ADC CRDMO business after the listing
The Zhitong Finance App learned that Yao Ming United (02268) surged by more than 5% in the afternoon. As of press release, it had risen 5.01% to HK$17.6 million, with a turnover of HK$2016.67 million. Guoxin Securities pointed out that as the ADC CRDMO leader with a global layout, Pharmaceutical Federation has established a fully integrated one-stop CRDMO platform, covering the entire ADC CRDMO service process and leading the world in comprehensive capabilities. As the company's global production capacity continues to expand and pre-IND projects continue to advance to the post-IND stage, we believe that the company's business will maintain rapid growth over the next 3 years. Tianfeng Securities, on the other hand, said that
Pharmaceutical Federation (02268.HK): Strong profitability highlights the advantages of continuous expansion of integration
The business is growing rapidly, and the forward-looking integrated layout highlights the company's competitive advantage. According to the company's performance announcement, in 2023, the company achieved operating income of 1,224 million yuan, an increase of 114.4% over the previous year; achieved gross profit of 560 million yuan
Pharmaceutical Federation (02268.HK): Performance doubled, the ADC circuit wave has arrived
Event summary The company announced its 2023 annual results on March 25, 2024. In 2023, it achieved revenue of 2,124 billion yuan, an increase of 114% over the previous year; adjusted net profit of 412 million yuan, an increase of 11 percent over the previous year
Pharmaceutical Federation (02268.HK): Rapid growth in performance, integrated CRDMO platform empowers the entire ADC production and development process
Annual performance grew rapidly, and revenue and profit performance was impressive. Revenue for the full year of 2023 was $2,124 million (+114.44%), and net profit attributable to mother was $284 million (+82.07%). Refund of listing expenses and shares
Pharmaceutical Federation (02268.HK): Steadily Promoting Global Production Capacity Construction, Abundant Ongoing Orders, Ensuring High Growth
Excellent performance in 2023, with plenty of uncompleted orders to guarantee high future performance growth. In 2023, the company achieved revenue of 2.69 billion yuan, an increase of 114.3% over the previous year; net profit to mother was 284 million yuan, an increase of 82 million yuan over the previous year
Pharmaceutical Federation (2268.HK): Performance is in line with expectations, XDCCRDMO leaders are growing rapidly
Core view Pharmaceutical Federation released its 23-year performance report. The company achieved annual revenue of 2.12 billion yuan and adjusted net profit of 410 million yuan, an increase of more than 100% over the previous year. Reserve orders increased 82% year over year. The company signed a new contract in '23
Pharmaceutical Federation (2268.HK): Revenue and profit are growing rapidly, and on-hand orders are abundant. It is expected that multiple PPQ projects will be completed in 2024, and the long-term development of the one-stop conjugated drug CRDMO is optim
Incident The company announced 2023 results: in 2023, operating income of 2.124 billion yuan (+114%), gross margin of 26.3% (-0.1pp), adjusted net profit of 412 million yuan (+112)
Most of the Hong Kong pharmaceutical stocks rebounded, and Ming Union surged nearly 10% to lead the market
① What was the performance of Pharmaceutical Federation last year? ② How does the agency view this performance?
Changes in Hong Kong stocks | Yao Ming Union (02268) rose more than 6%. Institutions believe that performance is high, growth expectations have been fulfilled, and that current stock prices are still significantly undervalued
Pharmaceutical Federation (02268) rose more than 6% and rose 6.57% at press time to report HK$18.16, with a turnover of HK$18.65 million.
No Data